Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

In 5subjects with type 2 diabetes uncontrolled on metformin and basal insulin, the DUAL VII trial (NCT02420262) demonstrated that a once-daily injection of insulin degludec/liraglutide (IDegLira) was non-inferior to multiple injections of basal-bolus therapy (insulin glargine 100 units/mL + insulin aspart before each main meal) for A1C reduction, and was associated with a significantly lower risk of hypoglycemia. This non-prespecified post-hoc analysis examined whether the efficacy results persisted across sub-groups for six different variables and evaluated whether benefits seen in the trial were applicable across a broad patient population. After 26 weeks of treatment, there was no significant difference in A1C reduction between IDegLira compared with basal-bolus in any baseline characteristic group (A1C, BMI, age, diabetes duration, total daily insulin dose and fasting plasma glucose [Table]). Additionally, there was no significant interaction between treatment and baseline sub-group for any of the baseline characteristics (Table). In conclusion, the A1C lowering was comparable between once-daily IDegLira vs. basal-bolus therapy after 26 weeks of treatment, irrespective of baseline characteristics, which underscores the general application of these findings to a broad patient population.